Hematological Toxicity in Mice after High Activity Injections of <sup>177</sup>Lu-PSMA-617

Prostate cancer (PC) is one of the most common malignancies affecting men, with poor prognosis after progression to metastatic castration-resistant prostate cancer (mCRPC). Radioligand therapy (RLT) targeting the overexpressed PSMA on PC cells, with, e.g., <sup>177</sup>Lu-PSMA-617, has...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Amanda Kristiansson, Oskar Vilhelmsson Timmermand, Mohamed Altai, Joanna Strand, Sven-Erik Strand, Bo Åkerström, Anders Örbom
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: MDPI AG 2022-03-01
Cyfres:Pharmaceutics
Pynciau:
radioligand therapy
<sup>177</sup>Lu-PSMA-617
prostate cancer
mouse model
hematotoxicity
Mynediad Ar-lein:https://www.mdpi.com/1999-4923/14/4/731
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg